search
Back to results

The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy

Primary Purpose

Neuromuscular Diseases, Spinal Muscular Atrophy Type 3

Status
Recruiting
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
Aerobic Exercise Training
Home exercise program
Sponsored by
Istanbul Medipol University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neuromuscular Diseases focused on measuring Spinal Muscular Atrophy Type 3, Aerobic Training, SMN protein level, Physiotherapy

Eligibility Criteria

10 Years - 50 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Have been diagnosed of SMA Type 3 confirmed by genetic analysis,
  • Between the ages of 10-50,
  • Being able to walk 25 m without assistive device

Exclusion criteria:

  • Using research drugs for SMA treatment other than Nusinersen treatment,
  • Having a serious systemic disease that may prevent exercise,
  • Have had a lower extremity injury and/or surgery in the last 6 months,
  • To be applying a regular aerobic training program in the last 6 months

Sites / Locations

  • Istanbul Faculty of Medicine, Department of Neurological SciencesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Aerobic Exercise Training Group

Control Group

Arm Description

Aerobic training will be performed 3 days a week for 12 weeks at 60% -%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group. Home exercise program will be given. This home program will include stretching, breathing, normal joint movement for 3 to 5 days a week

Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 or 5 days a week.

Outcomes

Primary Outcome Measures

Functional Capacity
Change from baseline functional capacity test at 12 weeks. Functional capacity will be assessed by the 6 minute walking test.The 6MWT, an objective evaluation of functional capacity, measures the maximum distance a person can walk in six minutes over a 25-meter linear course.

Secondary Outcome Measures

Submaximal Exercise Test
Change from baseline Submaximal Exercise Capacity Test at 12 weeks. It will be evaluated by Incremental Submaximal Exercise Test. The tests will be performed by using an cycle ergometer.
Pulmonary Function
Change from baseline Forced Vital Capacity (FVC) in respiratory function test at 12 weeks. Pulmonary Function will be assessed by measuring forced expiratory vital capacity (FVC) as percent predicted for age and height.
Motor Function
Change from baseline Hammersmith Functional Motor Scale, Expanded (HFMSE) at 12 weeks . The HFMSE is a 33-item scale designed for SMA type 2 and 3 patients.Items are scored on a 0-2 scale with a full score of 2 being normal without assistance, a partial score of 1 requiring a modified method but no assistance, and a zero score being unable to achieve the task without assistance.
Motor Performance
Change from baseline 10 Meter Walk/Run Test at 12 weeks . This test measures the time it takes a subject to walk or run 10 meters as fast as possible without compromising the subject's safety.
Balance and Mobility
Change from baseline Timed Up and Go Test (TUG) Test at 12 weeks The TUG test, which is a method to assess balance and mobility, measures the time it takes an individual to stand up from a chair, walk 3 meters, turn around, and sit down in the same chair.Ten seconds or less indicate normal mobility.
Muscle strength
Change from baseline Manual Muscle Testing (MMT) at 12 weeks Manual muscle testing (MMT) augmented by hand held dynamometry (HHD) provides a comprehensive evaluation of muscle strength.
Quality of Life in patients with neuromuscular disease
Change from baseline quality of life scale at 12 weeks The Pediatric quality of life™ 3.0 Neuromuscular Module (PedsQL™ 3.0 NMM) was designed to assess health-related quality of life (HRQoL) among aged 2-18 years with NMD.The scale consists of 25 items under 3 categories. .Items are scored on a Likert-type scale from 0 (never poses a problem) to 4 (always poses a problem). Scoring is between 0-100 .Higher scores from the Module indicate better health-related quality of life.For patients 18 years and older, The Short Form (SF-36), a widely used health-related quality of life measure. The Short Form (SF-36) Health Survey is a 36-item, patient-reported survey of patient health.
Fatigue
Change from baseline Fatigue Scale at 12 weeks. The PedsQL Multidimensional Fatigue Scale comprises parallel child self-report and parent proxy-reportformats. A 5-point response scale is utilized across child and a dolescent self-report for ages 8-18 and paren proxy-report . Items are reverse scored and linearly transformed to a 0-100 scale.Higher PedsQL Multidimen-sional Fatigue Scale scores indicate better HRQOL. The Fatigue Severity Scale (FSS) is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in adult patients with a variety of disorders .A self-report scale of nine items about fatigue,The higher the score, the more severe the fatigue is and the more it affects the person's activities.
Functional Lower Extremity Strength,
Change from baseline Five Times Sit to Stand Test at 12 weeks. The five Times Sit to Stand Test( 5XSS) scoring is based on the amount of time a patient is able to transfer from a seated to a standing position and back to sitting five times. The lower the time to complete the test the better the outcome of the test. The Minimal Detectable Change(MDC) time for the test is within 3.6 to 4.2 second and Minimal clinically important difference (MCID) is 2.3 seconds.
Evaluation of SMN protein levels in blood biochemistry
Change from baseline SMN protein levels at 12 weeks. The response of patients' SMN protein levels to exercise will be evaluated before and after 12 weeks of training.

Full Information

First Posted
August 19, 2022
Last Updated
September 27, 2023
Sponsor
Istanbul Medipol University Hospital
Collaborators
Istanbul University
search

1. Study Identification

Unique Protocol Identification Number
NCT05544994
Brief Title
The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy
Official Title
The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy"
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 28, 2022 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
September 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Istanbul Medipol University Hospital
Collaborators
Istanbul University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
In the last 10-15 years, a better understanding of the pathophysiology and molecular genetics of SMA has led to the emergence of previously unavailable pharmacological and genetic treatments.One of these new treatments, Nusinersen, targets SMN2, which is a slightly different copy of SMN1, and increases SMN protein levels. Preclinical studies have provided evidence that neuroprotection is strongly formed, with exercise significantly increasing motor neuron survival independent of SMN expression. In a limited number of clinical studies prior to Nusinersen treatment, it was reported that aerobic exercise training improved maximum oxygen uptake (VO2 max) without causing muscle damage, but still caused fatigue. The aim of this study is to determine the effect of aerobic exercise training on motor and respiratory functions, exercise capacity, fatigue and quality of life in SMA Type III patients who can walk and receive Nusinersen therapy. Twenty cases aged 10-50 years with genetically confirmed SMA diagnosis will be included in this study. The cases to be included in the study will be randomized into 2 groups as the training and control groups. In addition to the routine physiotherapy program, medium-intensity Aerobic Exercise Training will be given to the study group for 12 weeks. Before and 12 weeks after the training, the cases will be evaluated with the Six Minute Walking Test, Submaximal Exercise Test, SMN protein level, function and strength assessments, (FVC) value, fatigue and quality of life scales. In clinical trials, the supporting evidence for aerobic interventions in SMA is limited. Additional studies on aerobic intervention parameters (frequency, intensity and duration) are needed.The results of this study will determine the feasibility of aerobic exercise training and provide important guidance for the clinical management of SMA patients.
Detailed Description
Spinal Muscular Atrophy (SMA) is a neuromuscular disorder characterized by degeneration of alpha motor neurons in the spinal cord, leading to progressive muscle atrophy and weakness. Mutation or deletion of the survival motor neuron1 (SMN1) gene causes insufficient production of the SMN protein, which ensures motor neuron survival and maintenance in the spinal cord. In the last 10-15 years, a better understanding of the pathophysiology and molecular genetics of SMA has led to the emergence of previously unavailable pharmacological and genetic treatments. One of these new treatments, Nusinersen targets SMN2, which is a slightly different copy of SMN1, increases SMN protein levels. Preclinical studies have provided evidence that exercise significantly increases motor neuron survival independent of SMN expression, and that neuroprotection is strongly formed. In a limited number of clinical studies prior to Nuinersen therapy, it was reported that aerobic exercise training improved maximum oxygen uptake (VO2 max) without causing muscle damage, but still caused fatigue and had no significant beneficial effect on physical functioning. This study aims to determine the effect of aerobic exercise training on motor and respiratory functions, exercise capacity, fatigue and quality of life in SMA Type III patients who can walk and receive Nusinersen treatment. Twenty patients between the ages of 10 and 50 with genetically confirmed SMA diagnosis will be included in this study. The patients will be randomly divided into 2 groups as the training and control groups. In addition to the routine physiotherapy program, the study group will be given a moderate-intensity Aerobic Exercise Training for 12 weeks. Before and after 12 weeks of training, subjects will be evaluated with the Six-Minute Walk Test, ,Submaximal Exercise Test, SMN protein level and function and strength assessments, (FVC) value, fatigue and quality of life scales. In clinical trials, the supporting evidence for aerobic interventions in SMA is limited. It has been reported that SMA patients cannot tolerate excessive exercise intensity and that recovery may be prevented due to excessive fatigue. Additional studies on aerobic intervention parameters (frequency, intensity and duration) are needed. The results of this study will determine the feasibility of aerobic exercise training and will have an impact on clinical practice by providing important guidance to the clinical management of SMA patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuromuscular Diseases, Spinal Muscular Atrophy Type 3
Keywords
Spinal Muscular Atrophy Type 3, Aerobic Training, SMN protein level, Physiotherapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Aerobic Exercise Training Group
Arm Type
Experimental
Arm Description
Aerobic training will be performed 3 days a week for 12 weeks at 60% -%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group. Home exercise program will be given. This home program will include stretching, breathing, normal joint movement for 3 to 5 days a week
Arm Title
Control Group
Arm Type
Active Comparator
Arm Description
Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 or 5 days a week.
Intervention Type
Other
Intervention Name(s)
Aerobic Exercise Training
Intervention Description
Aerobic training will be performed 3 days a week for 12 weeks at 60%-%75 of their maximum hearth rate with 30 minutes total duration consisting of 5 min warm up and 5 min cool down period in treatment group.
Intervention Type
Other
Intervention Name(s)
Home exercise program
Intervention Description
Home exercise program will be given. This home program will include stretching, breathing, normal joint movement, for 3 to 5 days a week.
Primary Outcome Measure Information:
Title
Functional Capacity
Description
Change from baseline functional capacity test at 12 weeks. Functional capacity will be assessed by the 6 minute walking test.The 6MWT, an objective evaluation of functional capacity, measures the maximum distance a person can walk in six minutes over a 25-meter linear course.
Time Frame
Baseline and 12 weeks
Secondary Outcome Measure Information:
Title
Submaximal Exercise Test
Description
Change from baseline Submaximal Exercise Capacity Test at 12 weeks. It will be evaluated by Incremental Submaximal Exercise Test. The tests will be performed by using an cycle ergometer.
Time Frame
Baseline and 12 weeks
Title
Pulmonary Function
Description
Change from baseline Forced Vital Capacity (FVC) in respiratory function test at 12 weeks. Pulmonary Function will be assessed by measuring forced expiratory vital capacity (FVC) as percent predicted for age and height.
Time Frame
Baseline and 12 weeks
Title
Motor Function
Description
Change from baseline Hammersmith Functional Motor Scale, Expanded (HFMSE) at 12 weeks . The HFMSE is a 33-item scale designed for SMA type 2 and 3 patients.Items are scored on a 0-2 scale with a full score of 2 being normal without assistance, a partial score of 1 requiring a modified method but no assistance, and a zero score being unable to achieve the task without assistance.
Time Frame
Baseline and 12 weeks
Title
Motor Performance
Description
Change from baseline 10 Meter Walk/Run Test at 12 weeks . This test measures the time it takes a subject to walk or run 10 meters as fast as possible without compromising the subject's safety.
Time Frame
Baseline and 12 weeks
Title
Balance and Mobility
Description
Change from baseline Timed Up and Go Test (TUG) Test at 12 weeks The TUG test, which is a method to assess balance and mobility, measures the time it takes an individual to stand up from a chair, walk 3 meters, turn around, and sit down in the same chair.Ten seconds or less indicate normal mobility.
Time Frame
Baseline and 12 weeks
Title
Muscle strength
Description
Change from baseline Manual Muscle Testing (MMT) at 12 weeks Manual muscle testing (MMT) augmented by hand held dynamometry (HHD) provides a comprehensive evaluation of muscle strength.
Time Frame
Baseline and 12 weeks
Title
Quality of Life in patients with neuromuscular disease
Description
Change from baseline quality of life scale at 12 weeks The Pediatric quality of life™ 3.0 Neuromuscular Module (PedsQL™ 3.0 NMM) was designed to assess health-related quality of life (HRQoL) among aged 2-18 years with NMD.The scale consists of 25 items under 3 categories. .Items are scored on a Likert-type scale from 0 (never poses a problem) to 4 (always poses a problem). Scoring is between 0-100 .Higher scores from the Module indicate better health-related quality of life.For patients 18 years and older, The Short Form (SF-36), a widely used health-related quality of life measure. The Short Form (SF-36) Health Survey is a 36-item, patient-reported survey of patient health.
Time Frame
Baseline and at 12 weeks
Title
Fatigue
Description
Change from baseline Fatigue Scale at 12 weeks. The PedsQL Multidimensional Fatigue Scale comprises parallel child self-report and parent proxy-reportformats. A 5-point response scale is utilized across child and a dolescent self-report for ages 8-18 and paren proxy-report . Items are reverse scored and linearly transformed to a 0-100 scale.Higher PedsQL Multidimen-sional Fatigue Scale scores indicate better HRQOL. The Fatigue Severity Scale (FSS) is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in adult patients with a variety of disorders .A self-report scale of nine items about fatigue,The higher the score, the more severe the fatigue is and the more it affects the person's activities.
Time Frame
Baseline and 12 weeks
Title
Functional Lower Extremity Strength,
Description
Change from baseline Five Times Sit to Stand Test at 12 weeks. The five Times Sit to Stand Test( 5XSS) scoring is based on the amount of time a patient is able to transfer from a seated to a standing position and back to sitting five times. The lower the time to complete the test the better the outcome of the test. The Minimal Detectable Change(MDC) time for the test is within 3.6 to 4.2 second and Minimal clinically important difference (MCID) is 2.3 seconds.
Time Frame
Baseline and 12 weeks
Title
Evaluation of SMN protein levels in blood biochemistry
Description
Change from baseline SMN protein levels at 12 weeks. The response of patients' SMN protein levels to exercise will be evaluated before and after 12 weeks of training.
Time Frame
Baseline and 12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Have been diagnosed of SMA Type 3 confirmed by genetic analysis, Between the ages of 10-50, Being able to walk 25 m without assistive device Exclusion criteria: Using research drugs for SMA treatment other than Nusinersen treatment, Having a serious systemic disease that may prevent exercise, Have had a lower extremity injury and/or surgery in the last 6 months, To be applying a regular aerobic training program in the last 6 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sezan Mergen KILIÇ, MSc PT
Phone
05324569628
Email
sezanmer@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sezan Mergen KILIÇ, MSc PT
Organizational Affiliation
Istanbul University, Istanbul Faculty of Medicine,Department of Neurological Sciences
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Fatma Karantay Mutluay,, Professor
Organizational Affiliation
Medipol University, Health Sciences Faculty, Physiotherapy and Rehabilitation
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Fatma Yeşim Parman, Professor
Organizational Affiliation
Istanbul University, Istanbul Faculty of Medicine,Department of Neurological Sciences
Official's Role
Study Director
Facility Information:
Facility Name
Istanbul Faculty of Medicine, Department of Neurological Sciences
City
Istanbul
State/Province
Fatih
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sezan Mergen KILIÇ, MSc PT
Phone
05324569628
Email
sezanmer@hotmail.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy

We'll reach out to this number within 24 hrs